公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial | Reich K.; Gooderham M.; Tha?i D.; Crowley J.J.; Ryan C.; Krueger J.G.; TSEN-FANG TSAI ; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C. | The Lancet | 191 | 157 |